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Background: The number of systematic reviews (SRs)/meta-analyses (MAs) has increased dramatically in China
over the past decades. However, evaluation of quality of reporting of systematic reviews published has not been
undertaken. The objective of this study is to evaluate the quality of reporting of SRs/MAs assessing efficacy and/or
harms of clinical interventions published in “evidence-based” Chinese journals.
Methods: Web-based database searches were conducted for the Chinese Journal of Evidence-based Medicine,
the Journal of Evidence-Based Medicine, the Chinese Journal of Evidence Based Pediatrics, and the Chinese Journal
of Evidence-Based Cardiovascular Medicine. SRs/MAs assessing efficacy and/or harms of clinical interventions were
included. The cut-off was December 31st 2011. The PRISMA statement was applied to assess the quality of reporting.
Each item was assessed as follows: ‘Yes’ for total compliance, scored ‘1’; ‘partial’ for partial compliance, scored ‘0.5’; and
‘No’ for non-compliance, scored ‘0’. The review was considered to have major flaws if it received a total score of ≤15.0,
minor flaws if it received a total score of 15.5 to 21.0, and minimal flaws if it received a total score 21.5 to 27.0. Odds
ratios were used for binary variables, and the mean difference was used for continuous variables. Analyses were
performed using RevMan 5.0 software.
Results: Overall, 487 SRs/MAs were identified and assessed. The included reviews had medium quality with minor
flaws based on PRISMA total scores (range: 8.5–26.0; mean: 19.6 ± 3.3). The stratified analysis showed that SRs/MAs with
more than 3 authors, from a university, hospital + university cooperation, multiple affiliations (≥2), and funding have
significantly higher quality of reporting of SRs/MAs; 58% of the included reviews were considered to have minor flaws
(total score of 15.6 to 21.0). Only 9.6% of reviews were considered to have major flaws. Specific areas needing
improvement in reporting include the abstract, protocol and registration, and characteristics of the search.
Conclusions: The reporting of SRs published in “evidence-based” Chinese journals is poor and needs to be improved
in order for reviews to be useful. SR authors should use the PRISMA checklist to ensure complete and accurate
accounts of their SRs.
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Clinicians refer to systematic reviews (SRs)/meta-analyses
(MAs) to keep up to date with developments in their field.
High quality SRs/MAs of randomized controlled trials can
provide the best evidence [1]. In order to assess the quality
of reporting of SRs/MAs, complete, clear, and transparent
information with regards to the design and conduct* Correspondence: tianjh@lzu.edu.cn
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unless otherwise stated.of the SRs/MAs are required; however, to date, this
information it is not optimal and the low quality of
reporting diminishes the value of SRs/MAs for clinicians,
policy makers, and other users [2].
In order to improve the quality of reporting of SRs/MAs,
an international group of experienced authors and
methodologists developed the Preferred Reporting Items of
Systematic Reviews and Meta-Analyses (PRISMA) [3],
which itself was a successor to the original QUOROM
guidelines [4]. It contains a 27-item checklist and a 4-phasehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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tial for transparent reporting of a SR [2].
A few studies have examined the reporting quality of
SRs/MAs in various fields, and found that the reporting
quality of SRs/MAs was poor with many flaws [5-8].
Recently, the concept of evidence-based medicine has
widely spread across China through the Chinese Journal of
Evidence-based Medicine (CJEBM), the Journal of Evidence-
Based Medicine (JEBM), the Chinese Journal of Evidence-
Based Pediatrics (CJEBP), and the Chinese Journal of
Evidence-Based Cardiovascular Medicine (EBCVM) [9]. In
this study, we sought to determine the degree to which
studies published in these four journals met the PRISMA
criteria for reporting, whether it had improved after publi-
cation of the PRISMA statement, and factors associated
with good reporting.
Methods
Sample collection, selection, data extraction, and qual-
ity assessment were performed independently by two
trained reviewers; disagreements between reviewers
were resolved through consensus or by consulting a third
expert adjudicator.
Selection of studies
An inclusion criterion was that the words SR and/or
MA were stated in the title of studies. Using this criterion,
we searched the online databases of the CJEBM
(www.cjebm.org.cn, 2001 to December 31st, 2011), the
JEBM (www.jebm.cn, 2001 to December 31st, 2011), the
CJEBP (www.cjebp.net, 2006 to December 31st, 2011) and
the EBCVM (www.ebcvm.org, 2008 to December 31st,
2011) for SRs and MAs. Only reviews assessing the safety
and/or efficacy of clinical interventions were included. A
total of 487 SRs and MAs on interventions were included
after reading the title, abstract, and full-text.
Data extraction
We established a spreadsheet using Microsoft Excel
2003. In addition to the items in PRISMA, the following
data were extracted from each study: i) title; ii) first
author name; iii) the name of the journal; iv) the number of
author(s); v) year of publication; vi) the authors’ affiliations
(hospital or university) and the number of affiliations; vii)
financial support; viii) categories of diseases (ICD-10) [10];
and ix) the number of included studies.
Statistical analysis
PRISMA was used to evaluate the adherence of review
articles to scientific principles. The tool covers seven
modules with 27-items: title, abstract, introduction,
methods, results, discussion, and funding. Each of the
items were assessed as follows: ‘Yes’ for total compliance,
scored ‘1’; ‘partial’ for partial compliance, scored ‘0.5’; and‘No’ for non-compliance, scored ‘0’; with a total maximum
score ‘27’. The review was considered to have major flaws
if it received a total score of ≤15.0, minor flaws if it
received a total score of 15.5 to 21.0, and minimal
flaws if it received a total score 21.5 to 27.0 [11].
The percentage of reports that met each criterion was
determined and tabulated. Data on each item was
presented as counts and percentages. The odds ratio
(OR), 95% CI, mean, standard deviation (SD), and mean
difference (MD) were used as the summary statistics for
stratified comparisons with RevMan software version 5.0.
Statistical significance was set at P ≤0.05.
Stratified analysis
We assessed the following variables as potentially associ-
ated with differences in the quality of reporting: publication
time (≤2009 vs. ≥2010), the number of authors (≤2 vs. ≥3),
the authors’ affiliations (hospital vs. university), the number
of affiliations (1 vs. ≥2), and funding sources (funding vs.
non-funding) [12].
To assess whether publication of the PRISMA statement
was associated with improved reporting of certain items,
we compared overall compliance in each PRISMA item
using the t-test (≤2009 vs. ≥2010).
Results
Description of included reviews
Four hundred and eighty seven studies were included for
evaluation; 77.8% (379/487) of SRs/MAs were published
in CJEBM, 14.4% (70/487) of SRs were published in
JEBM, 6.2% (30/487) of SRs were published in CJEBP,
and EBCVM published 1.6% (8/487) of SRs/MAs. The first
SR was published in 2001, and the total number increased
to 89 in 2009. Twenty categories of diseases were involved
according to ICD-10 and the most common conditions
studied were neoplasms (17.4%, 83/487). The reviews
included a median of four authors (range: 1–12) and
87.7% (427/487) of the studies were written by ≥3 authors;
almost half (43.3%) of the reviews were written by clinicians.
Financial support was obtained by 25% (122/487) of the
reviews. The reviews included a median of 8 randomized
controlled trials (range: 1–129).
The overall reporting quality of included reviews
Overall, the compliance with PRISMA was poor, none of
the included reviews fulfilled all 27-items of PRISMA.
Table 1 shows that the weakest areas within the included
SRs/MAs were the reporting of protocol and registration
information (item 5, 0.4%), risk of bias across studies
(item 22, 22.4%), additional analyses (item 23, 29.2%),
and funding sources (item 27, 24.4%). The reasons for
particularly low reporting for item 5 may be that there is
no existing register for SRs/MAs in China, and the rela-
tively rare publication of SR/MA protocols. Some PRISMA
Table 1 The results of reporting quality assessment (n = 487)
PRISMA items Yes Partial No
n (%) 95% CI n (%) 95% CI n (%) 95% CI
Title 1. Title 476 (98) 96–99 1 (0) 1–1 10 (2) 1–4
Abstract 2. Structured summary 256 (53) 48–57 226 (46) 42–51 5 (1) 0–2
Introduction 3. Rational 429 (88) 85–91 55 (11) 9–14 3 (1) 0–2
4. Objective 335 (69) 65–73 143 (29) 26–34 9 (2) 1–4
Methods 5. Protocol and registration 2 (0) 0–2 58 (12) 9–15 427 (88) 85–90
6. Eligibility criteria 447 (92) 89–94 39 (8) 6–11 1 (0) 1–1
7. Information sources 480 (99) 97–100 6 (1) 0–23 1 (0) 0–1
8. Search 263 (54) 50–59 182 (37) 33–41 42 (9) 6–12
9. Study selection 241 (50) 45–54 72 (15) 12–18 174 (36) 32–40
10. Data collection process 334 (69) 64–73 45 (9) 7–12 108 (22) 19–26
11. Data items 203 (42) 37–46 25 (5) 4–8 259 (53) 49–58
12. Risk of bias in individual studies 436 (90) 87–92 17 (4) 2–6 34 (7) 5–10
13. Summary measures 444 (91) 88–93 7 (1) 0–3 36 (7) 5–10
14. Synthesis of results 453 (93) 90–95 7 (1) 0–3 27 (6) 4–8
15. Risk of bias across studies 161 (33) 29–37 74 (15) 12–19 252 (52) 47–56
16. Additional analyses 253 (52) 48–56 44 (9) 7–12 190 (39) 35–43
Results 17. Study selection 356 (73) 69–77 70 (14) 12–18 61 (13) 10–16
18. Study characteristics 445 (91) 89–94 21 (4) 3–7 21 (4) 3–7
19. Risk of bias with studies 423 (87) 84–90 31 (6) 5–9 33 (7) 5–9
20. Results of individual studies 442 (91) 88–93 24 (5) 3–7 21 (4) 3–7
21. Synthesis of results 442 (91) 88–93 23 (5) 3–7 22 (5) 3–7
22. Risk of bias across studies 109 (22) 19–26 94 (19) 16–23 284 (58) 54–63
23. Additional analyses 142 (29) 25–33 56 (11) 9–15 289 (59) 55–64
Discussion 24. Summary of evidence 440 (90) 87–93 38 (8) 6–11 9 (2) 1–4
25. Limitations 385 (79) 75–83 42 (9) 6–12 60 (12) 10–16
26. Conclusions 394 (81) 77–84 85 (18) 14–21 8 (2) 0–3
Funding 27. Funding 119 (24) 21–28 41 (8) 6–11 327 (67) 63–71
Total score Scope 8.5–26.0
±SD 19.60 ± 3.33
Figure 1 The overall scores for PRISMA.
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Figure 2 Comparison of pre-PRISMA and post-PRISMA periods for each PRISMA item.
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title (item 1, 97.7%), eligibility criteria (item 6, 91.8%),
information sources (item 7, 98.6%), summary measures
(item 13, 91.2%), synthesis of results (methods section)
SRs/MAs(item 14, 93.0%), study characteristics (item
18, 91.4%), results of individual studies (item 20,
90.8%), synthesis of results (results section) SRs/MAs
(item 21, 90.8%), and summary of evidence (item 24,
90.3%). The overall quality scores are shown in
Figure 1. The range and mean ± SD of overall quality score
for included SRs/MAs was 8.5 to 26.0 and 19.6 ± 3.3,
respectively; 47 (9.6%) studies had major flaws (an over-
all score of ≥15), 284 (58.3%) had minor flaws (an over-
all score of 15.5 to 21.0), and 156 (32%) were
considered to have minimal flaws (an overall score of
21.5 to 27.0).Figure 3 Stratified analysis of included SRs/MAs.Did the quality of SRs/MAs improve post-PRISMA?
To investigate whether the publication of the PRISMA
statement was associated with an improvement in report-
ing for certain items (pre-PRISMA vs. post-PRISMA), the
period ≤2009 was compared with ≥2010 in each of the
PRISMA statement. Figure 2 shows that, following
publication of the PRISMA statement, the quality of
reporting improved; the difference was statistically
significant for following items: item 1 (P = 0.0006), item 6
(P = 0.0006), item 8 (P = 0.04), item 9 (P <0.0001), item 11
(P <0.00001), and item 14 (P = 0.0002).
Stratified analysis
To assess possible factors associated with reporting quality,
we analyzed the publication time (≤2009 vs. ≥2010), the
number of authors (≤2 vs. ≥3), the affiliation of authors
Table 2 Comparison of overall PRISMA scores in the four assessed journals [n (%)]
CJEBM (n = 379) JEBM (n = 70) CJEBP (n = 30) EBCVM (n = 8) Total (n = 487)
≤15 25 (7) 22 (31) 0 0 47 (10)
~21 226 (60) 43 (61) 10 (33) 5 (63) 284 (58)
~27 128 (34) 5 (7) 20 (67) 3 (38) 156 (32)
Range 8.5–26 8.5–23 18.5–24.5 18–21.5 8.5–26
Mean ± SD 19.97 ± 3.15 16.60 ± 3.22 21.77 ± 1.52 20.19 ± 1.41 19.60 ± 3.33
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and funding sources (funding vs. non-funding), as
shown in Figure 3. The overall quality scores of SRs/MAs
published post-PRISMA was significantly different, with a
mean difference of –1.18 (95% CI: –1.76 to –0.60). The
overall quality score of SRs/MAs written by ≥3 authors
showed no statistically significant difference compared to
by 1 to 2 authors (MD: –0.8 [95% CI: –1.8 to 0.2]). SRs
conducted within universities (MD: –0.6 [95% CI: –1.3
to 0.1]) or hospital + university cooperation (MD: –0.9
[95% CI: –1.7 to –0.3]) were better reported than those
conducted outside from hospitals. SRs conducted by
authors with more than two affiliations were better than
one affiliation (MD: –0.3 [95% CI: –0.9 to 0.4]), and
funded reports demonstrated a statistically significant
difference when compared with non-funded reports
(MD: 0.9 [95% CI: 0.3 to 1.6]).
Comparison of overall PRISMA scores in the four journals
assessed
Table 2 shows that the overall quality score of SRs/MAs
published in the four journals demonstrated minor flaws
(58.3%), and we found that the quality of reporting of
SRs/MAs published in CJEBP (21.8 ± 1.5) was better
when compared with the remaining journals (19.5 ± 3.4)
(MD: 2.3 [95% CI: 1.7 to 2.9], P <0.00001).
Discussion
The number of SRs/MAs published in China has been
accumulating at an increasing rate in recent years.
However, the results of our study indicate that the quality
of the SRs/MAs is not optimal.
The best reported items (addressed completely >90.0%)
included identification of a SR/MA by its title, eligibility
criteria, information sources (such as the database or
key words searched), summary measures, synthesis of
results (methods section), study characteristics, results
of individual studies (results section), synthesis of results
(results section), and summary of evidence (results section).
A great deal of improvement is required in the following
items (addressed completely 50% to 90%): structured sum-
mary, rational, search, data collection process, risk of bias
in individual studies (methods section), additional analyses
(methods section), study selection, risk of bias with studies
(results section), limitations, and conclusions. Furthermore,there was seriously flawed reporting (addressed completely
50% or less) in protocol and registration, study selection
(methods section), data items (methods section), risk
of bias across studies (methods section), risk of bias
across studies (results section), additional analyses (results
section), and funding sources.
Further, the registration of protocols was rarely
performed. We expect that a network of registration
for SRs will be established in China, thus facilitating
the registration and reporting of protocols. The main
reason most studies scored poorly on details of the
search strategy was that only 19.7% reviews reported the
detailed search strategy; most reviews only reported the
databases and key words. Chinese journals should demand
that authors provide the detailed search strategy.Conclusions
SRs or MAs related to efficacy and safety of clinical
interventions published in “evidence-based” Chinese
journals had minor flaws. Efforts should be made to
improve the reporting of a structured abstract, objectives,
protocol and registration, search strategy, data extracted,
risk of bias across studies, additional analyses, and funding
sources reporting. Meanwhile, SR authors should use
the PRISMA checklist to ensure complete and accurate
accounts of their SRs.Abbreviations
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